18 stories found
Cytokinetics announced additional clinical trial results for its ACACIA-HCM and MAPLE-HCM programs during a late-breaking session at the European Society of Cardiology Congress, advancing treatments for hypertrophic cardiomyopathy.
Cytokinetics CEO Robert Blum has sold 7,500 shares of the company's stock for a total of $575,700 in an insider transaction.
An analysis reveals the hypothetical value of a $100 investment in Cytokinetics made ten years ago, illustrating its long-term performance.
Citi has identified Cytokinetics, Incorporated (CYTK) as a 'top pick' among small-to-mid cap biotechnology stocks, highlighting its potential for investors.
Cytokinetics (CYTK) has reached a 52-week high in its stock price, driven by a dramatic increase in revenues, soaring over 1,000%.
Biopharmaceutical firm Cytokinetics announced its first complete quarter of sales for its drug MYQORZO, while hedge fund Armistice Capital expanded its ownership position during the same period. The developments highlight growing institutional interest despite broader market pressures in the biotech sector.
Details concerning dividends from Cytokinetics Inc. are provided.
An analysis questions whether Cytokinetics, Incorporated (CYTK) is currently a good stock investment.
Cytokinetics announced it has priced an upsized equity raise of $700 million at $71 per share.
Key highlights from Cytokinetics' first-quarter earnings call have been released, detailing the company's financial performance.
Cytokinetics, Incorporated (CYTK) is positioned to gain market share with its drug Myqorzo in the cardiac myosin treatment sector.
Cytokinetics has released comprehensive results from its late-stage clinical trial demonstrating significant efficacy for a novel therapy treating non-obstructive hypertrophic cardiomyopathy. The findings were presented at the European Society of Cardiology congress and published in a leading medical journal.
Cytokinetics aims for over 50% MYQORZO new-to-brand share by the end of 2026 and plans a New Drug Application (sNDA) for nHCM in Q4.
Cytokinetics (CYTK) has introduced its drug MYQORZO in Germany, intended for the treatment of obstructive hypertrophic cardiomyopathy (HCM).
Cytokinetics has projected its operating expenses to be between $830 million and $870 million for 2026, while also progressing with the launch of its product MYQORZO in Germany.
Cytokinetics (CYTK) has published the transcript of its first-quarter 2026 earnings call, detailing the company's financial performance and strategic updates.
Truist highlighted Cytokinetics, Incorporated's (CYTK) operational investments aimed at supporting short-term growth.